Wed, April 23, 2025
Tue, April 22, 2025
Mon, April 21, 2025
[ Mon, Apr 21st ] - ZDNet
Fitbit is dying a slow death
Sun, April 20, 2025
Sat, April 19, 2025
Fri, April 18, 2025
Thu, April 17, 2025
Wed, April 16, 2025
Tue, April 15, 2025
Mon, April 14, 2025
Sun, April 13, 2025
Fri, April 11, 2025
Thu, April 10, 2025
Sun, April 6, 2025
[ Sun, Apr 06th ] - Yahoo
health and-fitness
Sat, April 5, 2025
Fri, April 4, 2025
Mon, March 31, 2025
Sun, March 30, 2025
Sat, March 29, 2025

Eli Lilly and Novo Nordisk are tackling heart health next


//health-fitness.news-articles.net/content/2025/ .. novo-nordisk-are-tackling-heart-health-next.html
Published in Health and Fitness on by Quartz   Print publication without navigation

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.

Eli Lilly and Novo Nordisk, known for their diabetes and obesity treatments, are now focusing on cardiovascular health. Both companies are exploring the potential of their GLP-1 receptor agonists, like Ozempic and Mounjaro, in reducing heart-related risks. These drugs, initially developed for managing blood sugar, have shown in clinical trials to also lower the risk of major adverse cardiovascular events (MACE) such as heart attacks and strokes. Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) are at the forefront, with ongoing studies like the SELECT trial for Wegovy, which aims to confirm cardiovascular benefits in a broader population. This shift towards heart health could expand the market for these medications, potentially transforming treatment paradigms for cardiovascular diseases.

Read the Full Quartz Article at:
[ https://www.msn.com/en-us/health/weightloss/eli-lilly-and-novo-nordisk-are-tackling-heart-health-next/ar-AA1C1fC9 ]

Publication Contributing Sources